BCR-ABL1 Quantitative p210 p190 p230 Test
Comprehensive Genetic Testing for Leukemia Monitoring
The BCR-ABL1 Quantitative p210 p190 p230 test represents a breakthrough in molecular diagnostics for hematological malignancies. This sophisticated genetic analysis plays a crucial role in the management and treatment monitoring of patients with chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). By detecting and quantifying specific chromosomal abnormalities, this test provides healthcare providers with essential data to guide treatment decisions and assess therapeutic effectiveness.
What Does the BCR-ABL1 Test Measure?
This advanced molecular test specifically detects and quantifies three critical BCR-ABL1 fusion transcripts:
- p210 Transcript: Associated with chronic myeloid leukemia (CML)
- p190 Transcript: Primarily linked to Philadelphia chromosome-positive acute lymphoblastic leukemia
- p230 Transcript: Associated with chronic neutrophilic leukemia
The test utilizes Real-Time PCR technology to provide precise quantification of these fusion genes, enabling accurate monitoring of disease burden and treatment response over time.
Who Should Consider This Test?
This test is recommended for individuals experiencing or diagnosed with:
- Newly diagnosed chronic myeloid leukemia (CML)
- Suspected or confirmed Philadelphia chromosome-positive ALL
- Patients undergoing tyrosine kinase inhibitor therapy
- Individuals with unexplained fatigue, night sweats, or unexplained weight loss
- Patients with abnormal blood counts requiring further investigation
- Individuals requiring treatment response monitoring
Key Benefits of BCR-ABL1 Testing
- Accurate Diagnosis: Provides definitive confirmation of BCR-ABL1 positive leukemias
- Treatment Monitoring: Enables precise tracking of treatment effectiveness
- Early Detection: Identifies molecular relapse before clinical symptoms appear
- Personalized Therapy: Guides treatment adjustments based on molecular response
- Prognostic Information: Helps predict disease progression and outcomes
Understanding Your Test Results
Your BCR-ABL1 test results will provide quantitative information about the presence and level of fusion transcripts:
- Positive Result: Indicates the presence of BCR-ABL1 fusion genes, confirming diagnosis
- Quantitative Levels: Shows the percentage of BCR-ABL1 transcripts relative to control genes
- Treatment Response: Decreasing levels indicate positive response to therapy
- Molecular Relapse: Rising levels may indicate disease progression or resistance
Always discuss your results with your healthcare provider for proper interpretation and treatment planning.
Test Pricing and Details
| Test Feature | Details |
|---|---|
| Test Name | BCR-ABL1 Quantitative p210 p190 p230 |
| Regular Price | $300 USD |
| Discount Price | $226 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Bone Marrow / Peripheral Blood |
| Test Method | Real-Time PCR |
Nationwide Availability
We have testing facilities conveniently located across the United States, serving patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.
Book Your Test Today
Take control of your health with our comprehensive BCR-ABL1 testing service. Our experienced team is ready to assist you with scheduling and answer any questions you may have about the testing process.
Call or WhatsApp us today: +1(267) 388-9828
Don’t wait to get the critical information you need for proper leukemia management and treatment monitoring. Our discounted price of $226 USD makes this essential testing accessible and affordable for all patients.
